Immune effector cell associated neurotoxicity syndrome ICANS
CAR-T Toxicities: CRS and ICANS
Treating CRS and ICANS: current approaches and future outlooks
Module 2: Toxicity Assessment and Management | ICANS
What is ICANS?
Mechanisms and management of short- and long-term CAR-T toxicities
CAR-T: symptoms and their assessment
Insights into the clinical management of CAR-related toxicities
Bispecific Antibodies: Late Side Effects
Optimizing CAR-T therapy: regulating CAR T-cells in vivo
Identifying and managing patients at high risk of developing toxicities following CAR-T therapy
Updates in the management of CAR-T toxicities
The role of microglia in the pathophysiology of ICANS following CD19 CAR-T therapy
Management of CRS and ICANS after CAR-T therapy for ALL
IFN-beta-1a for preventing toxicities after CD19-directed CAR T-cell therapy: a trial in progress
Managing the side effects of CAR-T therapies
Management of CAR-T related side effects
The management of CAR-T related toxicities in leukemia and lymphoma
Siltuximab for the management of CAR-T toxicities: a multicenter retrospective study